Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 862 results for "gilead sciences"

Gilead's Sovaldi cleared in Japan for HCV-2

News Editor The Japanese Ministry of Health, Labour and Welfare approves Gilead Sciences' (NASDAQ:GILD) Sovaldi (sofosbuvir) for the suppression of viremia in patients with chronic hepatitis C genotype 2 infection, with or without compensated ... Seeking Alpha, 3 days ago

173 images for gilead sciences

American Banking News, 6 days ago
CTV News, 4 days ago
Free-i-News, 1 week ago
West Australian, 6 days ago, 4 days ago
Drug Discovery and Development, 5 days ago
Jutia Group, 6 days ago
Drug Discovery and Development, 1 week ago
Jutia Group, 2 weeks ago
Bidness Etc, 4 weeks ago

Cipla revs up for generic Sovaldi launch in India

Gilead's Sovaldi--Courtesy of Gilead Cipla is rolling out its low-cost version of Gilead Sciences' ($GILD) hep C powerhouse Sovaldi in India. With a launch planned this week, Cipla will become the latest company to field a Sovaldi copycat under ...
 FiercePharma4 days ago Cipla to launch generic version of Hepatitis C drug Sovaldi  Livemint.com3 days ago Cipla to launch generic Hepatitis C drug 'Hepcvir' in India  Moneycontrol.com4 days ago Zydus Cadila Launches Generic Version of Gilead Sciences’ Hepatitis C drug in India  TopNews1 week ago

Gilead Warns of Cardiac Issues With Sovaldi and Harvoni

Gilead Sciences Inc. said 9 patients taking its hepatitis C drugs Harvoni or Sovaldi along with the heart treatment amiodarone developed abnormally slow heartbeats and 1 died of cardiac arrest. Three required a pacemaker to be inserted. Gilead said ...
 American Journal of Managed Care5 days ago Gilead warning of hepatitis C patient death on heart medication expected to have 'zero impact'  Pharmacist.com5 days ago Gilead warns of fatal reaction to Sovaldi, Harvoni and heart drug  FiercePharma6 days ago Gilead (GILD) Warns After Nine Hepatitis Patients Taking Heart Drug Develop Condition, One Dies From Cardiac Arrest 3/24/2015  ClinicSpace4 days ago

Next Resistance Level for Gilead Sciences (GILD) is $102.17

Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $100.23 and have already reached the first level of resistance at $101.22. Should the shares continue to rise, the resistance pivots of $102.17 and $104.11 will be
 Individual.com5 days ago Gilead Sciences (GILD) Approaches New Upside Target of $102.17  Individual.com5 days ago Gilead Sciences (GILD) Crosses Pivot Point Resistance at $102.10  Individual.com1 week ago
Business Recorder

US stocks mixed as Gilead Sciences and Monsanto fall

About 35 minutes into trade, the Dow Jones Industrial Average stood at 18,176.37, up 48.72 points
 Yahoo! UK and Ireland6 days ago US stocks mixed  NineMSN Finance6 days ago Wall Street extends gains at open  Business Spectator6 days ago US stocks mixed - Gilead Sciences, Monsanto fall  Finance 246 days ago

Biotech giant Gilead could have some major problems with its 'wonder drug' (GILD)

Gilead Sciences could have some problems with two of its biggest drugs. Bloomberg reported on Saturday that Gilead sent warnings to health providers on Friday after patients taking its hepatitis C drugs Sovaldi or Harvoni developed problems when ...
 Austin American Statesman1 week ago Why Is Everything Cheaper in India?  Free-i-News4 days ago

Gilead Sciences Shares Sinking Lower, Down 1.7%

Down 1.9% to $100.36, Gilead Sciences (NASDAQ:GILD), is one of today's notable movers. The Dow is up 0.3% to 18,181 and the S&P is currently trading fractionally higher
 Individual.com6 days ago Gilead Safety Warning? No Problem, Says Wall Street  Benzinga.com5 days ago Gilead Shares Reacting To Death Of Patient  Benzinga.com6 days ago Analysts Remain Bullish On Gilead Despite Safety Warning  Investing.com5 days ago

Biotech done? And an under-the-radar top stock

Source: Gilead Sciences For my latest "New Ideas" column for CNBC Pro, I discuss the dollar-oil link, a biotech bubble and the hottest stock of
 CNBC5 days ago Biotech Behemoth Gilead In Trouble After Flagship Drug Related Death  Zero Hedge6 days ago The Best Of The Best: Don't Miss These Top 9 Stocks  Investor's Business Daily4 days ago Bubble Bursting? 3 Top Stock Biotech Stocks to Buy  Nasdaq4 days ago
American Banking News

Wells Fargo & Co. Analysts Give Gilead Sciences a $125.00 Price Target (GILD)

Wells Fargo & Co. set a $125.00 target price on Gilead Sciences (NASDAQ:GILD) in a report issued on Monday. The firm currently has a a buy rating on the stock. A number of other firms have also recently commented on GILD. Analysts at Argus ...
 SleekMoney4 days ago Wells Fargo says recent weakness is a buying opp for Gilead  Seeking Alpha5 days ago Gilead Sciences Given a $125.00 Price Target by Wells Fargo & Co. Analysts (GILD)  American Banking News6 days ago
CTV News

Gilead hepatitis C drug approved for Canadian health plan

NEW YORK -- Gilead Sciences said multiple Canadian provinces will provide access to the Foster City company's hepatitis C drug Harvoni following a positive reimbursement recommendation from regulators. The recommendation means that both Harvoni ...
 SiliconValley.com5 days ago Gilead Sciences : hepatitis C treatment Harvoni accepted in Canadian health reimbursement plan  4 Traders5 days ago Hep C treatment Harvoni accepted in Canadian health reimbursement plan  CTV News4 days ago Gilead's hepatitis C treatment Harvoni accepted in Canadian health reimbursement plan  Canadian Business Magazine5 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less